ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GMBH
Radeberg, SN
- UEI
- LAHNMPWWFFJ9
- CAGE
- CD963
- Primary NAICS
- 325411 Medicinal and Botanical Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- International Organization
- Corporate family
-
-
- NEKKLUGDMBJ3
- RZPNGD2Y8RN5
- Los Angeles, CA TW89N9UVR4L3
- WE1TB9L41Q75
-
- SAM.gov registration date
- Physical address
- 01 Radeberg, Germany
- Website
- abx.de
- Founded
- 1997
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $11,210 |
| FY2023 | $20,000 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GMBH, doing business as ABX GMBH, is an international organization registered to receive awards from the U.S. federal government since May 11, 2010. As a foreign-owned, for-profit limited liability company, ABX GMBH specializes in providing advanced biochemical compounds and research reagents to support biomedical research efforts. The company primarily supplies custom-ordered chemical compounds and specialized reagents to U.S. government agencies, particularly in support of drug research and development initiatives.
Recent federal contract awards to ABX GMBH highlight the company's focus on supplying critical materials for scientific research. In March 2024, the National Institute on Drug Abuse (NIDA) awarded ABX GMBH a $11,210 firm-fixed-price purchase order for custom quantities of the SDM-8 tin precursor compound in various vial sizes. Additionally, in August 2023, NIDA granted a $20,000 purchase order to ABX GMBH for reagents and synthesis cassettes specifically for F-DOPA production. Both contracts were awarded without set-aside designations and are to be performed in Baltimore, Maryland. These awards demonstrate ABX GMBH's capability to provide highly specialized biochemical compounds and research tools tailored to the needs of U.S. government agencies engaged in advanced drug research and development.
Quick answers
Is ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GMBH registered in SAM.gov?
Yes. ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GMBH's SAM.gov registration is active through February 25, 2027.
What is ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GMBH's CAGE code?
ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GMBH's CAGE code is CD963, and its Unique Entity ID (UEI) is LAHNMPWWFFJ9.
How much has ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GMBH received in federal contracts?
Federal contracts obligated $31,210 to ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GMBH in fiscal years 2023 through 2027.
What is ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GMBH's most recent federal award?
ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GMBH's most recent federal contract award is Pots 24-2260. Custom order, SDM-8 tin precursor 200 MG per vial(R)-SDM-8 STANDARD10 MG per vial(S)-SDM-8 STANDARD5 MG… (75N95024P00191), from National Institute on Drug Abuse (NIH), on March 19, 2024.
On GovTribe
See ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GMBH's full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors